FDA fast tracks psychadelic drug research following Trump's executive order, according to CNBC

The FDA's decision to fast track psychedelic drug research following Trump's executive order signals a potential shift in regulatory attitudes towards innovative therapies. This could influence investor sentiment toward biotech equities and create ripple effects across sectors sensitive to regulatory changes, particularly in pharmaceuticals and mental health treatments.